Transcreener® AMP² CD39 Assay

A High Throughput Assay for the Ectonucleotidase CD39 Based on the Transcreener Assay Platform

Discover CD39 Inhibitors with the Transcreener AMP2 Assay

The Transcreener AMP CD39 Assay directly measures cyclic AMP produced by ectonucleoside triphosphate diphosphohydrolase-1 (also known as ENTPD1, NTPDase1, Cluster of Differentiation 39 or CD39). By measuring the production of AMP researchers can effectively determine the activity of the CD39 enzyme. The assay provides a powerful tool to screen entire compound libraries for CD39 modulators to help find new therapeutics for diseases such as cancer.

CD39 is an Important Messenger for Purinergic Signalling

Ectonucleotidases are plasma membrane-bound enzymes with externally oriented active sites that metabolize nucleotides to nucleosides and are crucial for maintaining immune homeostasis. CD39,  hydrolyzes ATP and ADP to AMP.  AMP can further be processed to adenosine leading to a significant impact on many disease states. Recent studies have shown a key role for adenosine in immunosuppression in the tumor microenvironment, and ectonucleotidases are emerging as promising immuno-oncology targets.

Purinergic Signaling

Direct Detection of AMP to Measure CD39 Enzymatic Activity

CD39 Assay Schematic FP
CD39 Assay Schematic TR-FRET

Applications

  • Measure Enzymatic Activity of CD39
  • Screen Compound Libraries for CD39 inhibitors
  • Quantify Inhibitor Potency
  • Inhibitor Selectivity Profiling

Features

  • Direct detection of unlabeled AMP
  • Easy to use, homogenous, one step format
  • Robust Assay Z’ > 0.7 under initial velocity conditions
  • Far-red fluorescent readouts minimize compound interference
  • A safe, non-radioactive method
  • Available in FP or TR-FRET readouts

Easy-to-Use, Mix-and-Read, HTS-Ready Assay

The Transcreener CD39 Assay is in a simple, HTS-ready, mix-and-read format. Run your enzyme reaction, add Transcreener reagents, and read your plates. The assay is compatible with 96, 384, and 1536-well formats.

Detection of AMP Under CD39 Initial Velocity

The assay demonstrates linearity when raw data is converted to AMP using a standard curve. CD39 can use a variety of substrates. Here both ATP and ADP are shown under initial velocity conditions.

Human CD39 Enzyme Titration

Linear Response

cd39 Under Initial Velocity Conditions using ATP and ADP as substrates

Screen for Inhibitors & Perform SAR

The Transcreener CD39 Assay is designed for screening compound libraries in a high throughput format. Follow up SAR can also be performed using the assay to determine inhibitor potency with ease.

A 1600 compound subset from Chembridge Diversity Library was screened using CD39 and ATP in the Transcreener TR-FRET format resulting in 8 hits shown in green.

1600 Compound Pilot Screen

CD39 Pilot Screen

Acquire Accurate Dose Response Measurements

Robust Assay Yields Quality Data

 Z’ measurements using optimized CD39 reaction conditions indicate a robust assay.  Robust data like this is vital for sizeable high throughput screens that are difficult to complete due to massive sample quantity. Both ATP and ADP produce excellent results.

Robust Assay with Excellent Z prime

Far-Red FP & TR-FRET Readouts Validated on Major Multimode Readers

What's Included

What You Will Need

Transcreener AMP2 CD39 Assay Kits

* For custom or bulk orders (over 100,000 wells) please contact us (info@bellbrooklabs.com) for a quote.

In addition to our AMP CD39 Assay, Bellbrook Labs also offers the following products to aid in the drug discovery process:

Methyltransferase Assays

CD39 Assay Resources

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA

(608) 443-2400

info@bellbrooklabs.com

TOP